Summary
Pfizer Inc.'s 2014 10-K filing highlights a dynamic business landscape shaped by strategic divestitures, ongoing research and development investments, and significant international operations. The company's strategic shift towards a new global commercial structure, dividing operations into an Innovative Products business (GIP and VOC segments) and an Established Products business (GEP segment), aims to enhance focus and efficiency. The Innovative Products business drives growth through novel medicines, while the Established Products business provides stable cash flow and focuses on biosimilar development. Financially, biopharmaceutical revenues, accounting for the vast majority of total revenue, saw a slight decrease of 5% year-over-year, impacted by a 3% operational decline and a 2% unfavorable foreign exchange impact. Consumer Healthcare, however, showed growth. The company is actively managing its patent portfolio, with several key products facing upcoming patent expirations, underscoring the importance of its R&D pipeline and business development initiatives. Notably, Pfizer announced its intent to acquire Hospira, Inc. for approximately $17 billion, a move expected to bolster its position in injectable drugs and biosimilars, with the transaction anticipated to close in the second half of 2015.
Financial Highlights
56 data points| Revenue | $49.60B |
| Cost of Revenue | $9.58B |
| Gross Profit | $40.03B |
| SG&A Expenses | $14.10B |
| Operating Income | $9.09B |
| Interest Expense | $1.36B |
| Net Income | $9.13B |
| EPS (Basic) | $1.44 |
| EPS (Diluted) | $1.42 |
| Shares Outstanding (Basic) | 6.35B |
| Shares Outstanding (Diluted) | 6.42B |
Key Highlights
- 1Pfizer announced a definitive merger agreement to acquire Hospira, Inc. for approximately $17 billion, aiming to strengthen its position in injectable drugs and biosimilars.
- 2The company reorganized its commercial operations into two main businesses: Innovative Products (Global Innovative Pharmaceutical - GIP, and Global Vaccines, Oncology and Consumer Healthcare - VOC) and Established Products (Global Established Pharmaceutical - GEP).
- 3Biopharmaceutical revenues decreased by 5% in 2014 to $45.7 billion, influenced by a 3% operational decrease and a 2% unfavorable foreign exchange impact.
- 4Consumer Healthcare revenues increased by 3% to $3.4 billion, driven by operational growth.
- 5Pfizer invested $8.4 billion in Research and Development (R&D) in 2014, reflecting its commitment to innovation and pipeline development.
- 6International operations constituted 62% of total revenues in 2014, underscoring the company's global reach.
- 7Several key biopharmaceutical products experienced patent expirations or loss of regulatory exclusivity in various markets during 2014, highlighting the ongoing challenge of generic competition.